Listed by the USPTO as MOSELEY II, NELSON B
Tech Center 1600 • Art Units: 1642 1671
This examiner grants 68% of resolved cases
Nelson B. Moseley II works in Art Unit 1642 of Tech Center 1600. The examiner has a 67.9% allowance rate over 629 resolved cases. The interview lift is 41.7%, suggesting that interviews are highly effective for increasing the chances of an allowance. The median days to allowance is 1141, which provides a timeline for successful prosecution. These metrics are based on the 629 cases resolved by the examiner.
Top companies include Amgen Inc., Macrogenics Inc., and Bristol-Myers Squibb Company. Top firms are BALLARD SPAHR LLP, MEDLER FERRO WOODHOUSE & MILLS PLLC, and STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. The 67.9% allowance rate and 41.7% interview lift indicate that direct engagement with the examiner is a valuable strategy. The 1141 days to allowance is the median duration for reaching a final resolution in these cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18531312 | USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS | Non-Final OA | Bristol-Myers Squibb Company |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 17759382 | SELF-ASSEMBLING PRODRUGS AS IMMUNE BOOSTERS FOR CANCER IMMUNOTHERAPY | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17813100 | COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18316739 | Antibody Constructs for CLDN18.2 and CD3 | Final Rejection | AMGEN INC. |
| 18324773 | Zwitterion Polymer-Drug Conjugates | Non-Final OA | University of Utah Research Foundation |
| 18160386 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | Final Rejection | GENMAB A/S |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy67.9% of resolved applications examined by Nelson B Moseley II were allowed (629 resolved cases), compared with 38.5% across Art Unit 1642 over the last five years.
This examiner's interview lift is +41.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Nelson B Moseley II took 1,141 days on average from filing to allowance.
Nelson B Moseley II examines applications in Art Unit 1642 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
